Summit Therapeutics adds Dr. Mostafa Ronaghi to its Board of Directors

– USA, FL –  Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the appointment of Dr. Mostafa Ronaghi (Ph.D.) to its Board of Directors, effective immediately.

“We are excited to add Dr. Ronaghi to complement our excellent group of current board members. Mostafa has valuable experience in translating innovative concepts in genomics and sequencing that ultimately lead to advancements in patient care through his work at Illumina, Grail, and his continuing ventures. As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to our impressive executive team,” said Chairman and CEO, Robert Duggan.

About Dr. Mostafa Ronaghi

Dr. Ronaghi is the Co-Founder and Executive Board Member of Cellanome. Before founding Cellanome, he was CEO, SVP, and member of the Executive Leadership Team at Illumina, Inc. (Nasdaq: ILMN) from 2008 to 2021. While at Illumina, in 2016, Dr. Ronaghi co-founded GRAIL, a next-gen liquid biopsy platform for cancer detection. Before Illumina, Dr. Ronaghi was the Principal Investigator at the Stanford Genome Technology Center from 1999 to 2008. Throughout his prolific career, Dr. Ronaghi co-founded several other companies, including Pyrosequencing AB in 1997, ParAllele Biosciences in 2001, NextBio in 2004, Avantome in 2008, and Clear Labs in 2014, each of which sought to increase the understanding of particular diseases through next-generation sequencing (NGS), advanced genotyping, or other advanced technology. Dr. Ronaghi holds a Ph.D. in Biotechnology from the Royal Institute of Technology in Stockholm, Sweden.

“I am very pleased at the opportunity to join Summit’s Board of Directors,” said Dr. Ronaghi. “This extraordinary team and its mission to increase the quality and duration of patients’ lives while reducing trauma is unparalleled. I am optimistic about the potential for ivonescimab to make a meaningful difference to those facing serious unmet medical needs, and I am thrilled to work with Team Summit to help it achieve its mission and goals.”

About Summit Therapeutics

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase the potential duration of life, and resolve serious unmet medical needs.

Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market. We are headquartered in Miami, Florida, and we have additional offices in Menlo Park, California, and Oxford, UK.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.